EFFECT OF EMPAGLIFLOZIN AND METFORMIN IN DIABETIC RATS. EFFECT OF EMPAGLIFLOZIN AND ITS COMBINATION WITH METFORMIN IN EXPERIMENTALLY INDUCED MI IN DIABETIC RATS

      Аннотация: The objective of the present study was to evaluate cardio-protective effect of sodium glucose co-transporter-2 inhibitor alone and its combination with metformin in experimentally induced myocardial infarction in diabetic rats. Group I served as normal control and received vehicle (0.5% hydroxy ethyl cellulose) for 4 weeks and normal saline subcutaneously on 29th and 30th days. Group II served as diabetic-myocardial control and received STZ-NIC (65-120mg/kg, i.p) and Isoproterenol (85mg/kg, sc) on 29th and 30th days. Group III received STZ-NIC, ISO and Empagliflozin 5mg/kg. Group IV received STZ-NIC, ISO and Empagliflozin 10mg/kg. Group V received STZ-NIC, ISO and Empagliflozin 5mg/kg + Metformin 50mg/kg. Animals treated with the combination of Empagliflozin and Metformin showed significant inhibition in the elevated level of BG, CK-MB, LDH, AST, Troponin and lipid profile in diabetic animals compared to diabetic control (Group II) animals and Group III and IV animals receiving only Empagliflozin 5 mg/kg and 10 mg/kg respectively.

Ключевые слова: type 2 diabetes, Cardiovascular Disease, SGLT-2 transporter, Empagliflozin